The Lung Cancer Research Foundation announced a collaboration with AstraZeneca to fund over $900,000 in research grants focused on understanding resistance to epidermal growth factor receptor tyrosine kinase inhibitors and immune checkpoint inhibitors, including therapeutic approaches to overcome these mechanisms, as well as biomarkers of immune-mediated adverse events.
[Lung Cancer Research Foundation]
0